Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yikes...guess we'll have to take turns...
appreciate, cuz I can't pull one for some reason..just started trading? .24?
that might get ugly..it might turn into a death match.
You know how I love getting in early on strong plays...
Completely agree Monk. Could be a ground floor opp
I sure will...I saw it on Profitspi...but, I'll post the link for the Stockcharts.com add in a sec...
I'll put one in as well. I have a premium subscription to stockcharts
Biotechs are plus...especially under the coming Obama administration...
Kraig Biocraft Laboratories Research Report
Please send us an email and I'll send you the 25 page report on Kraig Biocraft Laboratories, Inc. (KBLB.OB)
QualityStocks
Scottsdale, Arizona
www.QualityStocks.net
480.308.0703 Office
Editor@QualityStocks.net
Ya know I tried but stockcharts doesnt have one, I put in a request, would you put one in as well?
Interesting company in the Biotech field. Looks interesting and definitely the best field for 2009 IMHO. Doing some more research
Seems like some good info in the ibox...and the chart aint to shabby either...I'll post one in a few...
just started myself....Ibox needs a little more info...LOL
peaked? multimullion is just the start probably...think bigger with more contracts! hundred million!
Arm wrestle ya for it...
Sounds like a lot of zeros to me...could get to be a fun play pretty quickly...did you check the chart yet...some nice steady gains...
great, I have to deal with you on this one too
whats up monk man..
tomorrows open .24 is MINE!
In the Ibox it says MULTIBILIION dollar industry........yeah my interest is peaked
Hey QS what is going on here? I like what I'm DDing thus far.
anything in particular you want me to know?
It does look interesting doesn't it...will certainly warrant some further digging...
HMMMMMMMMMMMM Fibers based on genetic engineering??????
Interesting developments going on here...think I might have to take a deeper look...
Up another 25% on top of yesterday's 185.71% gains!!!
Placing a Value on Kraig Biocraft Laboratories, Inc. (KBLB.OB) Technology
Emerging Growth Research, LLP recently completed a 25 page research report on Kraig Biocraft Laboratories, Inc. and its Spider Silk technology. To establish a value for the “super fiber,” the research bureau evaluated the success of DuPont’s Kevlar, which currently brings in more than $5 billion a year from sales of Kevlar. After the evaluation, Emerging Growth Research concluded that Kevlar is worth approximately $8 billion.
If Kraig Biocraft makes a substantial breakthrough in the laboratory and is able to further refine its technology to produce commercial amounts, the technology will be immediately worth potentially several hundred million dollars to one of the multinational corporations operating within the technical textiles industry. Recognizing the massive potential, Emerging Growth Research has established a $4.00 target price, which represents a market capitalization of $200 million.
In final remarks, the research bureau stated, “Should additional refinements be made and actual production of fibers commence resulting in the beginnings of a robust fast growing market for spider silk-based products, we believe the value of this technology could potentially skyrocket, ultimately being worth billions of dollars to the company’s investors. Shares of Kraig Biocraft Laboratories are clearly speculative, but offer some exciting appreciation possibilities in the future. It will surely be exciting to watch developments at this company over the coming years.
KBLB.OB is Focused on Unlocking a Massive Marketing Opportunity
Kraig Biocraft Laboratories, Inc. is participating in a market that is generally referred to as the “technical textiles” market. This market encompasses a wide range of products used for numerous applications. The specific sub-sectors the company is targeting can be broken down into two main areas: aramid fibers and ultra-high molecular weight polyethylene fibers.
The worldwide market for these fibers and other high performance technical fibers is currently estimated at approximately $90 billion per year, with the United States accounting for 50%+ of the market. According to a research report completed by Emerging Growth Research, the market has experienced significant growth over the past 10 years and is expected to continue to perform at a robust growth rate over the coming years.
While there are already man-made products well established in the marketplace, Kraig Biocraft’s spider silk contains certain properties that are superior to these synthetically derived products. For example, although Kevlar can be measured to have greater tensile strength versus spider silk on a pound per pound basis, the product pales in comparison to spider silk’s ability to absorb energy prior to fiber breakage. Additionally, products made using spider silk could be completely biodegradable, a feature that has been purposely engineered out of competing high-performance fiber products.
KBLB.OB to Introduce the Next Generation Super Fiber
Kraig Biocraft Laboratories, Inc. has focused their efforts on developing significant high-performance technical fibers and polymers utilizing their research related to spider genes to create a transgenic variety of silkworms capable of spinning a new “super fiber” that is either similar or an exact copy of natural spider silk, which is known as one of the strongest and most resilient fibers. For many years the textile and material science industries have tried to replicate spider silk, but have not been successful.
The company has acquired the exclusive rights, in their field of use, to the genetic sequences patented by the University of Wyoming and the genetic engineering technology developed by the University of Notre Dame. The company’s intellectual property portfolio also includes a separate US provisional patent application regarding certain methodologies, genetic sequences, organic polymers and composites of fibers.
Although the production of a “super fiber” is the primary focus at this time, Kraig Biocraft is also considering the production of other unique proteins utilizing transgenic silk worms as a protein expression platform. It is believe that there is a large viable market for these unique proteins within the pharmaceutical, biotechnology and other research driven industries.
The superior properties of spider silk have been known for a long time, and it's about time someone looked at this.
KBLB.OB: Why is Spider Silk Exciting Technology?
Kraig Biocraft Laboratories is a biotechnology company primarily focused on pursuing a unique protein expression system with the objective of producing the next generation of technical fibers. The company is utilizing state of the art genetic techniques in order to develop a transgenic silkworm capable of producing commercially viable amounts of spider silk.
Spider silk is known as one of the strongest fibers found in nature. The fiber is extremely elastic and resilient and has several properties that are unmatched by even the most exotic of man-made fibers. Spider silk has an unparalleled ability to absorb energy and dissipate it in a very controlled manner, making it especially attractive for applications where energy absorption is a key design factor.
One of spider silk’s most significant properties is its extreme resistance to breaking under strain. This characteristic makes spider silk particularly appealing for use as a “super fiber.” Pound for pound, spider silk is much stronger than steel with clear evidence of spider silk being at least five times stronger than steel of the same diameter.
There is little debate whether spider silk is superior over many other man-made and natural fibers for certain applications, however the issue is how to cost effectively produce spider silk in sufficient quantities. With Kraig Biocraft’s leading team of scientific experts and breakthroughs taking place in the lab, the world is closer than ever to experiencing the many benefits offered by this exciting technology.
KBLB.OB is Backed by a Team of Professionals who Believe in the Company’s Potential
Kraig Biocraft Laboratories, Inc. was founded by the current CEO Kim Thompson, who invented the company’s technology. Kraig Biocraft is a fully reporting organization and trades on the over-the-counter market under the stock symbol KBLB. Currently, there are about 50 million common shares outstanding, approximately 64% of which is being held by Mr. Thompson.
At Kraft Biocraft, Mr. Thompson functions as the overall coordinator for the company’s business operations, ongoing research and development. Several prominent genetic scientists, one at the University of Wyoming and another at the University of Notre Dame, have teamed up with the company to further develop its technologies. The laboratory staffs of these professors are also greatly contributing to the company’s efforts.
The University of Wyoming Foundation has contributed significant intellectual property to Kraft Biocraft and has a major shareholder stake in the company. A number of the major discoveries from these associated researchers have proven essential to the company’s product development efforts. According to a comprehensive report prepared by Emerging Growth Research, the company has acquired exclusive rights to university owned technologies and is able to use these rights in product development and commercialization.
The company defines its technology as a unique protein expression system that is potentially highly scalable and cost-effective in producing a variety of different proteins that can be marketed into the pharmaceutical, technical textiles and materials markets. This unique protein expression system, known as spider silk, is one of the strongest and most resilient fibers known to man.
KBLB.OB is Led by a Knowledgeable Board of Scientific Advisors
Malcolm. J. Fraser, Jr. Ph.D. earned his Ph.D from Ohio State University and performed postdoctoral research at Penn State University and Texas A&M University. At the Texan University, he played a key role in developing the genetic expression system which is now a widely used methodology for producing organic molecules, including pharmaceuticals, on an industrial scale.
Randy Lewis, Ph.D received his B.S. in chemistry from the California Institute of Technology, and his M.S. in chemistry and Ph.D. in Biochemistry from the University of California, San Diego. Dr. Lewis, internationally renowned for his work on spider silk, is the named inventor of a number of patents relating to spider silk polymers. He currently heads the Lewis Laboratory within the Department of Molecular Biology at the University of Wyoming. The study of spider silk polymers and their underlying genetics is a major focus of Dr. Lewis’s research.
Donald L. Jarvis, Ph.D. earned both his B.S. and M.S. in microbiology at Idaho State University, and received his Ph.D. in Virology at Baylor College of Medicine. In 1987 he undertook postdoctoral studies on glycoprotein biosynthesis at Texas A&M, and within two years Dr. Jarvis moved into an independent position at Texas A&M. Currently, Dr. Jarvis heads a research laboratory within the University’s Department of Molecular Biology which focuses on biochemistry, biosynthesis, and practical genetic engineering applications. He is the author or co-author of many scientific articles in the fields of biosynthesis, genetic engineering and biochemistry.
Dr. Bong-Hee Sohn Joins Kraig Biocraft Laboratories, Inc. (KBLB.OB)
A couple months ago, genetic engineer Dr. Bong-Hee Sohn joined Kraig Biocraft’s research and development team to develop new high performance polymers using spider silk gene sequences. Dr. Sohn earned her Ph.D. from Kyung-Hee Univ. in South Korea and has extensive research background. One of her areas of expertise in genetic engineering is the development of innovative methods for transgenic silkworm production.
CEO Kim K. Thompson stated, “Dr. Sohn has already made a significant impact on the pace and direction of our development program. This is a very exciting time for the Company and for the research laboratory. The University of Notre Dame hired Dr. Sohn to work on specific applications of genetic engineering in silkworm for polymer development and protein expression platform technologies, which are the Company’s major areas of focus.”
She continued, “We would like to express our congratulations to the research team for their foresight in initiating this addition and expansion. The Company is now fully on target for significantly accelerating the pace of its R & D.”
Kraig Biocraft has focused their efforts on developing and commercializing high performance polymers using spider silk gene sequences. The company intends to tap into the $92 billion market for high performance and technical fibers. Kraig Biocraft believes that spider silk is a “super fiber” that will have numerous commercial and consumer applications.
KBLB.OB Makes Significant Breakthrough in the Labs
Earlier this month, Kraig Biocraft Laboratories announced that its scientific team, including Dr. Malcolm Fraser, Dr. Wang, Dr. Sohn, and other members, have found a process capable of doubling the number of gene transfers performed, greatly increasing productivity of the spider silk and high performance polymer development program.
Kraig Biocraft is focused on developing and commercializing high performance polymers using spider silk gene sequences. The company intends to participate in the $92 billion market for high performance and technical fibers. Last year, Kraig Biocraft Laboratories signed an intellectual property and collaborative research agreement with the University of Notre Dame and has since then been a proud sponsor of scientific research within the university.
CEO Kim K. Thompson commented, “Until recently, we were performing approximately 200 to 400 micro-injections for DNA transfer on a weekly basis. With the huge increase in brain-power that resulted from the University of Notre Dame’s addition of Dr. Wang, Dr. Sohn and other scientists to the team, we have seen a dramatic increase in both the quality and quantity of the work performed. Significantly, we are currently performing approximately 1,000 gene transfers in a single week. That puts us well ahead of our development target. Every gene transfer performed has the potential to result in the development of a new polymer or high performance fiber.”
“The new research team is proceeding in a systematic fashion to optimize the procedures to generate a good number of transgenic,” said Dr. Fraser, a member of Kraig’s Scientific Advisory Board and the head of the University of Notre Dame laboratory where the gene insertions are taking place. “Based upon what I see happening in the laboratory and with this team of scientists, I have every expectation that this is going to be a very good year,” Dr. Fraser added.
“This heightened pace,” interjected Thompson, “has been accompanied by a reformulation of the DNA inserts. The increase in productivity has been so great that instead of using a single DNA construct, we are now using multiple constructs. This is a very exciting time for the research team and Kraig.”
Thanks for the analyst report and the new release Kemp and you are right this stock doesn't seem to have much of a following.
This doesn't seem to be a very active board - Here is the press release: http://biz.yahoo.com/pz/080724/147035.html
I ran across this analyst report today on the internet:
http://www.scribd.com/doc/4012223/KBLB-Analyst-ReportJuly-2008
Sold all of my shares for my own reasons but will still continue to moderate until further notice.
KBLB.OB News
Kim Thompson, CEO of Kraig Biocraft Laboratories, Inc. is the Featured Guest in an Audio Interview at SmallCapVoice.com
5/22/2008 7:00:00 AM (Business Wire)
AUSTIN, Texas--(BUSINESS WIRE)--SmallCapVoice.com, Inc. today announced that a new audio interview featuring Kim Thompson, CEO of Kraig Biocraft Laboratories, (OTCBB:KBLB - News), is now available at SmallCapVoice.com. Mr. Thompson provides his personal insight into the Companys exciting entry into the $127 Billion dollar technical textiles market and the growing relationship between the Company and the University of Notre Dame. The interview can be heard here at http://www.smallcapvoice.com/kblb/kblb-5-21-08.php.
Investors and potential investors can learn more about Kraig Biocraft Laboratories, Inc. via the SmallCapVoice.com Investor Fact Sheet here http://www.smallcapvoice.com/kblb/factsheet.html.
SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients financial news releases. SmallCapVoice.com also offers individual investors with all the tools they need to make informed decisions about the stocks they are interested in. Tools like our stock charts, stock alerts, and our investor fact sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and their services, please visit http://www.smallcapvoice.com/services.html.
For more information on Kraig Biocraft Laboratories please visit the Company's web site: http://www.KraigLabs.com.
Press Release Source: Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. Develops Synthetic Enzyme
Tuesday May 20, 6:00 am ET
DNA Sequence for New Enzyme is Mapped
In Vitro Testing of the Enzyme's Ability to Cleave the Targeted DNA
to Begin This Summer
LANSING, Mich., May 20, 2008 (PRIME NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTC BB:KBLB.OB - News) announced today that a leading university laboratory, working pursuant to Kraig's collaborative and sponsored research program, has mapped out the DNA sequence for a new enzyme. The new enzyme is being developed as an important part of the laboratories' work with Kraig in developing new high strength polymers based on spider silk. The enzyme will be used to cleave targeted DNA sequences so as to facilitate genetic manipulation for polymer synthesis.
ADVERTISEMENT
``We have designed the enzyme specifically to accelerate our work on spider silk polymers,'' said Dr. Malcolm Fraser, who is the head of the University of Notre Dame research laboratory conducting this work. ``The enzyme should be ready for in vitro testing this summer. Because the enzyme is site specific, it will only cleave our targeted DNA at the precise target point. It is the biochemical equivalent of a rifle shot.''
The development of the enzyme fulfills an important part of the Company's collaborative research plan with the University. ``This success is rightly credited to Dr. Fraser and his team,'' said Kraig's CEO Kim Thompson. ``With the mapping of this DNA sequence our development program has taken another big leap forward. The benefit to Kraig's work on spider silk polymers is immeasurable. We believe that this exciting finding will play an important role in the development of high strength polymers and platform technologies.''
Kraig Biocraft Laboratories is a technology company focused on the development of commercially significant high-performance polymers, technical fibers and diverse platform technologies. Based on proprietary genetic engineering technology, Kraig is working to develop and produce polymers and protein-based materials including spider silk for use in the multi-billion dollar technical fibers market.
For more information on Kraig Biocraft Laboratories please visit the Company's website: http://www.KraigLabs.com
Thanks for the tip on GCOG. I haven't bought any, but it opened my eyes to something. Thanks.
KRAIG BIOCRAFT LABORATORIES, INC Files SEC form 10-Q, Quarterly Report
5/13/2008 2:16:00 PM (EDGAR Online)
13-May-2008
Quarterly Report
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Caution Regarding Forward-Looking Information
Certain statements contained herein, including, without limitation, statements containing the words "believes", "anticipates", "expects" and words of similar import, constitute forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.
Such factors include, among others, the following: international, national and local general economic and market conditions: demographic changes; the ability of the Company to sustain, manage or forecast its growth; the ability of the Company to successfully make and integrate acquisitions; raw material costs and availability; new product development and introduction; existing government regulations and changes in, or the failure to comply with, government regulations; adverse publicity; competition; the loss of significant customers or suppliers; fluctuations and difficulty in forecasting operating results; changes in business strategy or development plans; business disruptions; the ability to attract and retain qualified personnel; the ability to protect technology; and other factors referenced in this and previous filings.
Given these uncertainties, readers of this prospectus and investors are cautioned not to place undue reliance on such forward-looking statements.
Plan of Operations
During the next twelve months, we expect to take the following steps in connection with the further development of our business and the implementation of our plan of operations:
We expect to spend approximately $150,000 on collaborative research and development of high strength polymers at the University of Notre Dame over the next twelve months. We believe that this research is essential to our product development. If our financing will allow, management will give strong consideration to accelerating the pace of spending on research and development within the University of Notre Dame's laboratories.
We expect to spend approximately $13,800 on collaborative research and development of high strength polymers and spider silk protein at the University of Wyoming over the next twelve months. We believe that this research is important to our product development. This level of research spending at the university is also a requirement of our licensing agreement with the university. If our financing will allow, management will give strong consideration to accelerating the pace of spending on research and development within the University of Wyoming's laboratories.
We will actively consider pursuing collaborative research opportunities with other university laboratories in the area of high strength polymers. If our financing will allow, management will give strong consideration to increasing the depth of our research to include polymer production technologies that are closely related to our core research
We will consider buying an established revenue producing company which is operating in the biotechnology arena, in order to broaden our financial base and increase our research and development capability. We expect to use a combination of stock and cash for any such purchase.
We will also actively consider pursuing collaborative research opportunities with university laboratories in areas of research which overlap the company's existing research and development. One such potential area for collaborative research which the company is considering is protein expression platforms. If our financing will allow, management will give strong consideration to increasing the breadth of our research to include protein expression platform technologies.
Limited Operating History
We have not previously demonstrated that we will be able to expand our business through an increased investment in our research and development efforts. We cannot guarantee that the research and development efforts described in this Registration Statement will be successful. Our business is subject to risks inherent in growing an enterprise, including limited capital resources, risks inherent in the research and development process and possible rejection of our products in development.
If financing is not available on satisfactory terms, we may be unable to continue expanding our operations. Equity financing will result in a dilution to existing shareholders.
Results of Operations for the Quarter Ended March 31, 2008.
Revenue for the quarter ended March 31, 2008 was $0. This compares to $0 in revenue for the preceding quarter ended March 31, 2007. No sales are anticipated during the next twelve months as the company will remain in the research and development stage.
Expenses for the quarter ended March 31, 2008 were $112,386. This compares to $110,022 in expenses during the three months ended March 31, 2007. Research and development expenses for the quarter ended March 31, 2008 were $15,925. This compares to $50,000 spent on research and development during the three months ended March 31, 2007. In addition, we had the following expenses during the three months ended March 31, 2008: general and administrative-$24,981, professional fees-$15,628, officer's salary-$51,967 and payroll taxes-$3,975. This compares to the same expenses during the three months ended March 31, 2007: general and administrative-$5,385, professional fees-$0, officer's salary-$49,024 and payroll taxes-$5,613.
Capital Resources and Liquidity
As of March 31, 2008 we had $68,502 in cash.
We believe we can not satisfy our cash requirements for the next twelve months with our current cash. Completion of our plan of operation is subject to attaining adequate financing. We cannot assure investors that adequate financing will be available. In the absence of such financing, we may be unable to proceed with our plan of operations.
We anticipate that our operational, and general & administrative expenses for the next 12 months will total approximately $400,000. We do not anticipate the purchase or sale of any significant equipment. We also do not expect any significant additions to the number of employees. The foregoing represents our best estimate of our cash needs based on current planning and business conditions. The exact allocation, purposes and timing of any monies raised in subsequent private financings may vary significantly depending upon the exact amount of funds raised and our progress with the execution of our business plan.
In the event we are not successful in obtaining financing, we may not be able to proceed with our business plan for the research and development of our products. We anticipate that we will incur operating losses in the foreseeable future. Therefore, our auditors have raised substantial doubt about our ability to continue as a going concern.
Critical Accounting Policies
Our financial statements and related public financial information are based on the application of accounting principles generally accepted in the United States ("GAAP"). GAAP requires the use of estimates; assumptions, judgments and subjective interpretations of accounting principles that have an impact on the assets, liabilities, revenue and expense amounts reported. These estimates can also affect supplemental information contained in our external disclosures including information regarding contingencies, risk and financial condition. We believe our use if estimates and underlying accounting assumptions adhere to GAAP and are consistently and conservatively applied. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions. We continue to monitor significant estimates made during the preparation of our financial statements.
Our significant accounting policies are summarized in Note 1 of our financial statements. While all these significant accounting policies impact its financial condition and results of operations, we view certain of these policies as critical. Policies determined to be critical are those policies that have the most significant impact on our financial statements and require management to use a greater degree of judgment and estimates. Actual results may differ from those estimates. Our management believes that given current facts and circumstances, it is unlikely that applying any other reasonable judgments or estimate methodologies would cause effect on our results of operations, financial position or liquidity for the periods presented in this report.
Recent Accounting Pronouncements
In June 2007, the Emerging SEC's Issues Task Force ("EITF") issued EITF No. 07-3, Accounting for Nonrefundable Advance Payments for Goods or Services to Be Used in Future Research and Development Activities, ("EITF 07-3"). EITF 07-3 provides guidance for upfront payments related to goods and services of research and development costs and is effective for fiscal years beginning after December 15, 2007. The Company is currently evaluating the impact of EITF 07-3 on its financial statements.
In June 2007, the EITF issued EITF No. 07-01, Accounting for Collaborative Arrangements, ("EITF 07-1"). EITF 07-1 provides guidance for companies in the biotechnology or pharmaceutical industries that may enter into agreements with other companies to collaboratively develop, manufacture, and market a drug candidate (Collaboration Agreements) and is effective for fiscal years beginning after December 15, 2007. The Company does not expect that EITF 07-01 will have an effect on its financial condition or results of operations.
In September 2006, the FASB issued Statement No. 157, Fair Value Measurements ("FAS 157"), which defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. FAS 157 is effective for financial statements issued for fiscal years beginning after November 15, 2007. The Company does not expect the adoption of FAS 157 to significantly affect its financial condition or results of operations.
In February 2007, the FASB issued Statement No. 159, The Fair Value Option for Financial Assets and Financial Liabilities, Including an amendment of SFAS 115 ("FAS 159"), which permits companies to choose to measure many financial instruments and certain other items at fair value. FAS 159 is effective for fiscal years beginning after November 15, 2007 and interim periods within those fiscal years. The Company is currently evaluating the effect FAS 159 will have on our consolidated financial position and results of operations
In December 2007, the Financial Accounting Standards Board (FASB) issued SFAS No. 160, "Noncontrolling Interests in Consolidated Financial Statements - an amendment of ARB No. 51". This statement improves the relevance, comparability, and transparency of the financial information that a reporting entity provides in its consolidated financial statements by establishing accounting and reporting standards that require; the ownership interests in subsidiaries held by parties other than the parent and the amount of consolidated net income attributable to the parent and to the noncontrolling interest be clearly identified and presented on the face of the consolidated statement of income, changes in a parent's ownership interest while the parent retains its controlling financial interest in its subsidiary be accounted for consistently, when a subsidiary is deconsolidated, any retained noncontrolling equity investment in the former subsidiary be initially measured at fair value, entities provide sufficient disclosures that clearly identify and distinguish between the interests of the parent and the interests of the noncontrolling owners. SFAS No. 160 affects those entities that have an outstanding noncontrolling interest in one or more subsidiaries or that deconsolidate a subsidiary. SFAS No. 160 is effective for fiscal years, and interim periods within those fiscal years, beginning on or after December 15, 2008. Early adoption is prohibited. The adoption of this statement is not expected to have a material effect on the Company's financial statements.
In March 2008, the FASB issued SFAS No. 161, "Disclosures about Derivative Instruments and Hedging Activities, an amendment of FASB Statement No. 133" (SFAS 161). This statement is intended to improve transparency in financial reporting by requiring enhanced disclosures of an entity's derivative instruments and hedging activities and their effects on the entity's financial position, financial performance, and cash flows. SFAS 161 applies to all derivative instruments within the scope of SFAS 133, "Accounting for Derivative Instruments and Hedging Activities" (SFAS 133) as well as related hedged items, bifurcated derivatives, and nonderivative instruments that are designated and qualify as hedging instruments. Entities with instruments subject to SFAS 161 must provide more robust qualitative disclosures and expanded quantitative disclosures. SFAS 161 is effective prospectively for financial statements issued for fiscal years and interim periods beginning after November 15, 2008, with early application permitted. We are currently evaluating the disclosure implications of this statement.
Off-Balance Sheet Arrangements
We do not have any outstanding derivative financial instruments, off-balance sheet guarantees, interest rate swap transactions or foreign currency contracts. We do not engage in trading activities involving non-exchange traded contracts.
KBLB...Upon further inspection there doesn't appear to be a connection. However, I've accidentally found this one and picked up a few shares just to keep it on a live watchlist. In at .40
I'll be keeping an eye out for their next filing. It's got my attention and I've put my token shares in my IRA. Time will tell if I decide to get more.
GLTY :)
Sorry KarinCA I don't get the connection between the two companies. Do you have a link to the news you are talking about, my internet connection has been down all weekend and I just got home so I'll try to investigate that better a little later. Thanks Jimmysteel.
KBLB...Did you notice GCOG news search on fidelity or equityfeed, brings KBLB up? I bought some today. lol
I wonder if any are buying GCOG based on that KBLB news or if they get their own news today?
May 8, 2008 - 9:09 AM EDT
Keros Capital Report: Kraig Biocraft Labs Extends Agreement With the University of Notre Dame Into 2009
LANSING, MI, May 8 /CNW/ - Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB) announced today it has just signed a renewal and expansion of its Collaborative Research and Intellectual Property Agreement with the University of Notre Dame. The agreement provides Kraig with exclusive licensing rights for the products and technology developed pursuant to the collaboration.
The collaborative and research agreement and university research plan will open up new opportunities for Kraig to develop pharmaceutical and diagnostic applications for its genetic engineering technology. However, the Company's primary focus will remain on the development of high performance, high tensile strength fibers.
This year, two provisional patents have already been filed by the university: Human Diagnostic Technologies and New Gene Splicing and Genetic Engineering Technologies - both are significant developments for KBLB bringing the company closer to tapping several multi billion dollar markets.
"We are elated that the successful and productive research and development program with the University of Notre Dame will continue into 2009," said CEO Kim Thompson. "With the new and expanded research plan now in place, we look forward to a fruitful year."
More information available at: http://www.KraigLabs.com
Kraig Biocraft Laboratories, Inc. to Employ Artificial DNA Sequences for Development of New Materials for Technical Textile Market and Albemarle chairman gives up role; CEO Rohr to take over
--(www.USEquityNews.com)-- 05/07/2008 - Basic Materials industry alert provided by U.S. Equity News. Kraig Biocraft Laboratories, Inc. (OTC BB: KBLB) announced recently that the Company, working in cooperation with leading university laboratories, is synthesizing DNA sequences for artificial spider silk based polymers. The artificial DNA which the Company is developing relates to the discovery of a chimera molecule, the subject of a 2008 provisional patent filing, which incorporates high strength spider silk proteins. ``Our artificial DNA sequences are designed for use in the development and production of a new class of high performance fibers,'' said Kraig's CEO Kim Thompson. ``We are developing these fibers, spider silk analogs, specifically to capture a share of the growing technical fibers market. This is the primary market for high strength fibers. The market for technical fibers is booming. Within two years it is projected to grow to $127 billion. We believe that these revolutionary materials will have tremendous potential in the technical textiles marketplace for high strength polymers.''
Just testing, working out a bug. Why did that do that.
Keros Capital Report: Kraig Biocraft Labs Continues To Close On The $127 Billion Technical Textile Market
LANSING, Mich., May 7 /CNW/ - Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB) announced today they are synthesizing DNA sequences for artificial spider silk based polymers. The artificial DNA which the Company is developing relates to the discovery of a chimera molecule, which incorporates high strength spider silk proteins.
"Our artificial DNA sequences are designed for use in the development and production of a new class of high performance fibers," said Kraig's CEO Kim Thompson. "We are developing these fibers, spider silk analogs, specifically to capture a share of the growing technical fibers market. This is the primary market for high strength fibers, projected to grow to $127 billion. The artificial DNA sequences are one of the keys to satisfying that demand."
Kraig Biocraft Laboratories is a technology company focused on the development of commercially significant high-performance polymers and technical fiber. Based on proprietary genetic engineering technology, Kraig is working to develop and produce polymers and protein-based materials including Spider Silk.
More information available at the Kraig Biocraft Laboratories company web site: http://www.KraigLabs.com
Followers
|
641
|
Posters
|
|
Posts (Today)
|
26
|
Posts (Total)
|
278292
|
Created
|
05/04/08
|
Type
|
Free
|
Moderators gimmegimmeminemine TRUISM EOT WebSlinger |
Email: corporate@KraigLabs.com
KRAIG LABS WEBSITE FOR INVESTORS
Quarterly and Annual Reporting to the SEC is available on the Company's Website and EDGAR.
* Financial Statements * SEC Filings *
Outstanding Shares as of January 12, 2023
For issues or questions relating to share certificates or the transfer of securities please contact the company's transfer agent:
Olde Monmouth Stock Transfer Co., Inc.
200 Memorial Pkwy.
Atlantic Highlands, New Jersey 07716
Phone: (732) 872-2727
(since August 14, 2013)
Kraig Biocraft Laboratories, Inc. (KBLB) is the first company with a commercially feasible spidersilk to be mass produced.
Kraig Labs is a biotechnology company focused on the development of commercially significant high performance polymers and technical fibers. Kraig Lab's focus has been on the production of a transgenic silkworm incorporating specific gene sequences from the golden orb weaving spider. These specific gene sequences inserted are to enable the silkworm to spin a new recombinant fiber which incorporates spider silk proteins. With the scientific breakthrough announced on September 29, 2010, Kraig Labs is now working to commercialize the transgenic silkworms to compete in the garment industry silk market. The value for the chinese raw silk market alone is 3-5 billion per annum. With the creation of 20 seperate transgenic silkworms, all with unique properties, Kraig Labs is now working at an accelerated pace to build upon their first generation transgenic organisms to develop their second generation of transgenic silkworm incorporating spider silk proteins. The scientists nearly doubled the strength of the silkworm with these specific spider gene insertions. Their second generation of transgenics are expected to be complete in 2011. These second generation organisms are to be compared with the strength, flexibility and resiliency of the native spider in which the gene sequences are derived from. These fibers which will match the strength of spider silk are expected to compete in the technical textiles market valued in excess of 120 billion per annum. The 3rd generation organisms are currently in the planning phase. These organisms are expected to spin fibers exceeding the strength of native spiders and may incorporate gene sequences that release an antibiotic, or to help reduce scarring with use in bandages.
Kraig Biocraft Laboratories has a sponsored research and development program with the University of Notre Dame, and the University of Wyoming. The genetic work is occurring at the University of Notre Dame, headed by Dr Malcolm Fraser, Phd. The gene sequences are derived from Dr. Randy Lewis's(University of Wyoming) patented gene sequences of the golden orb weaving spider. Kraig labs is paying for all expenses incurred for this research and development program, and thus Kraig Labs has exclusive global commercialization rights with the technologies developed, including methods, organisms, and fibers produced.
MANAGEMENT
Kim Thompson, Founder and CEO
As the CEO of the company, Mr. Thompson is the only member of the scientific advisory board who is also
a part of the corporation's management. His formal education lies in the fields of economics and law.
He received his B.A. in Applied Economics from James Madison College at Michigan State University.
He received his Juris Doctorate from the University of Michigan Law School in 1994.
Mr. Thompson founded Kraig Biocraft Laboratories in his pursuit of the development of new biotechnologies
with industrial applications. As chairman of the scientific advisory board, he brings a unique perspective,and
acts as the primary liaison between the advisory board and the corporation.
Mr. Thompson brings a wealth of experience in business management and consultation to Kraig. Following
the completion of his undergraduate degree, Mr. Thompson joined California Craftsman, Inc. as a
Vice-President with primary responsibility for both marketing and human resources.
Kim Thompson was the director of business development at Franchise Venture Partners, LLC. He subsequently
joined the firm of Shearson, Lehman, Hutton where he specialized in equity trading and research of small cap
companies. Mr. Thompson received the highest series seven score for all Shearson brokers in his class nationwide.
His experience in those small cap equity markets has proven to be invaluable both in his legal and business successes.
Prior to becoming a public company CEO, Mr. Thompson was the founder and senior litigation partner in a California
commercial law firm where he worked as corporate and litigation counsel to privately held and public companies.
His many accomplishments in corporate law include winning and collecting in full what his firm believes to have been
the largest award of lost profits in a California commercial arbitration up to that time. An important part of his work was
winning victories on behalf of corporate clients in disputes over intellectual property and distribution rights. He has
represented business clients ranging from small start ups and micro caps to Fortune 100 companies.
With a background in business leadership and in advising public and private corporations, Kim Thompson continues
to bring a unique perspective to the successful management of business. His extensive business and legal background
enables him to create practical solutions to business problems and seize opportunities for growth.
Mr. Thompson is a member of the Triple Nine Society for persons with documented genius level IQs (having tested above
the 99.9th percentile). He is also active in the realm of science and invention where he has to his credit a number of
provisional patent applications including innovations in the areas of biotechnology, organic polymers, genetic engineering
and magnetic field manipulation, among others.
Mr. Rice has over 13 years’ experience growing development stage businesses with a focus on technology development, commercialization, and go to market strategies. Mr. Rice holds a B.S. in Chemical engineering from Michigan Technological University.
Prior to joining Kraig Biocraft Laboratories Mr. Rice was the Director of Advanced Technologies for Ultra Electronics, AMI. In this role, Mr. Rice was responsible for the identification, capture, and execution of new technology programs. During his tenure with AMI, Rice secured more than twenty five million dollars in funded development programs from the US Department of Defense which his team successfully leveraged into commercially viable spinoff products. Mr. Rice was also responsible for technical sales, marketing, and promotion of AMI’s products and capabilities. Rice joined AMI as the third full time employee and helped to lead the organization through its rapid growth and ultimate acquisition by Ultra Electronics in 2011.
Earlier in his career Mr. Rice developed unique advanced manufacturing techniques, established and trained a production staff, led engineering development, authored numerous technical papers, and is a recognized subject matter expert. Mr. Rice holds 5 issued patents and numerous provisional patents.
Mr. Rice brings a history of transforming revolutionary ideas into viable commercial products.
Mr. Rice is currently completing his Masters of Business Administration through the Executive Program at the Eli Broad College of Business: Michigan State University.
Despite the huge potential of genetically modified animals outside of laboratory research, commercialisation of these animals has been extremely limited. Numerous factors, including negative consumer perception, regulatory hurdles, and limitations inherent to classical GM technologies, have kept the majority of GM animal applications within the realm of academic research. However genome editing using zinc finger nucleases could help develop new markets for the future commercialisation of GM animals.
Genetic modification is commonplace throughout the life sciences sector, from fundamental research to pharmaceutical testing. GM cellular and animal models are valuable tools for the study of many chronic diseases, the testing of pharmaceutical compounds and the development of new therapeutic strategies. Genetic modification also offers great benefits in vaccine and biopharmaceutical manufacturing, which rely heavily on the use of GM organisms for biomolecule design and production. Modifying the genome of an organism or cell line allows the incorporation of target biomolecules in specific biological contexts, as well as the transfer of a gene product from a low-producing organism to one that can produce on a commercial scale. These applications have been widely accepted for many years, with countless GM organisms approved for medical manufacturing applications by drug regulators in all major countries. Despite this widespread success within the research and pharmaceutical sectors, the use of GM organisms outside of these markets has been limited.
Despite the lack of broad acceptance for most commercial applications of GM animal products, this technology has been able to gain traction in a few market sectors. The most obvious application has been the commercialisation of transgenic animals for the production of biomolecules for therapeutic use. Cattle, sheep and goats have been used for large-scale production of antibodies, steroids and hormones - most notably insulin - for many years. In 2009, GTC Biotherapeutics received US FDA approval for bioproduction of a recombinant human antithrombin. This product - ATryn - is extracted from the milk of transgenic goats, and is the first approved biopharmaceutical to be produced using genetically engineered animals. Although this is a significant breakthrough for the commercialisation of GM animals, it is still within the pharmaceutical industry, and is a natural progression of existing cell-based technologies. Of potentially greater commercial interest is the extension of genetic engineering outside of this sector, into areas such as food production, textiles and even companion animals.
GM crops have been available in many countries since the early 1990s, and numerous cash crops - including sugar beet, soybean, corn and tomatoes - have been modified to improve resistance to disease, increase the rate of growth or enhance nutritional value. However, cultivation of these transgenic crops is generally tightly regulated, particularly within the European Union, and this, together with negative public opinion, has limited the more widespread development of GM technologies.
Similar to GM crops, many of the animals currently under development are intended to confer disease resistance, an application particularly suited to the use of zinc finger nuclease (ZFN) technology. Many diseases can be treated by the targeted deletion or modification of a host gene. With ZFNs, these targets can be modified with no footprint of genetic engineering. Due to the high costs of raising livestock, another area of focus in developing commercial GM animals has been increasing the rate of growth or size of animals. Among the first GM animals likely to be launched is a fast growing salmon from AquaBounty. The AquAdvantage Salmon is designed to reach market size in half the time of a wild type salmon, reducing costs for fish farmers and limiting the environmental impact of salmon farming by avoiding the need for ocean pens.
Although genetic engineering of animals for food is primarily driven by economic pressures, GM technologies have also been used in the companion animals market. In this sector, genetic modification can be used for practical purposes - such as the creation of hypoallergenic animals or the correction of heritable congenital defects which have arisen though inbreeding - or for purely cosmetic purposes, such as GloFish. The first example of a GM pet, GloFish are fluorescent zebrafish (Danio rerio) that have had genes encoding naturally fluorescent proteins (GFP, YFP, RFP) inserted into their genome. Developed by a group at the National University of Singapore, GloFish were originally created to develop live detection systems for water pollution. They were introduced as pets in the United States in 2003 following over two years of extensive environmental research and consultation. In Europe however, the sale and possession of GloFish is prohibited by rigorous legislation concerning the use of GM technologies.
By allowing precisely targeted insertion of spider genes and concomitant removal of endogenous silkworm silk genes at the same locus, ZFN technology offers the potential for development of transgenic silkworms which will produce native spider silk at commercially viable levels
Perhaps even more interesting from a commercial perspective is the use of GM animals in the manufacture of textiles. Silkworms - actually the larval form of the silkmoth Bombyx mori - have been used for the production of silk for thousands of years, with natural silk still produced by the cultivation of silkworms today. Silkworm cocoons are unwound to create linear silk threads, then re-spun into textiles in much the same way as cotton. Although the applications of silkworm silk are numerous, due to their unique physical and chemical properties, there is also widespread interest in the silks of several other insects.
Spider silk, in particular, offers numerous possibilities within the technical textiles industry, due to its incredible tensile strength and elasticity; characteristics which have not yet been replicated in synthetic materials. Like all insect silks, spider silk fibres consist of repetitive units of protein crystals separated by less structured protein chains. The exact properties and composition of each spider silk vary with its intended function. Major Ampullate or dragline silk, for example, is relatively hydrophobic with very high tensile strength and toughness, as it is used to form the outer rim and spokes of a web. In contrast, hydrophilic capture spiral silks, which form the inner structures of the web, are sticky and highly elastic to effectively entrap prey. This high degree of variability offers enormous potential for the textiles industry, raising the possibility of tailoring the properties of silk to create advanced technical fabrics, for applications such as bulletproof vests, parachute canopies and automobile airbags; biomedical applications, including sutures and tendon and ligament repair; new fabrics, for sportswear and clothing; and even microelectronics.
Although the use of spider silks for microsutures has recently been reported, more widespread application of spider silk technologies is currently limited by the difficulty in producing silks on a commercially viable scale. This is due to the difficulties of rearing spiders in large numbers, due to their highly territorial and cannibalistic nature. As a result, the harvesting of spider silk fibres is extremely time consuming and labour intensive, with production of the only known spider silk garment - an 11 foot by 4 foot shawl made from golden orb spider silk - taking 150 people over five years to produce and costing in excess of £300,000!
.
To overcome these limitations, and allow future development of spider silk technologies, an alternative strategy for spider silk production is required. This makes spider silk production an obvious candidate for genetic modification, inserting spider silk genes into the genome
of other silk-making insects for bioproduction. For example, random insertion of orb spider silk genes into silkworms has allowed production of hybrid spider/silkworm silk using traditional silkworm farming strategies. The resulting hybrid silk contains approximately 10% spider silk
and has greater strength and durability than native silkworm silk, raising the possibility of using transgenic silkworms to produce pure spider silks.
Though straightforward in principle, the exchange of native silkworm genes for spider silk genes, alongside more widespread exploitation of genetic engineering, has been limited by the inherent restrictions of conventional GM technologies.
The generalised process of modifying an organism requires several capabilities, including:
While many different techniques exist for accomplishing each of these steps, most GM technologies offer a compromise between the efficiency of the technique and the ability to accurately and precisely target the locus of interest. Viral genomic delivery technologies effectively deliver nucleic acids to cells and organisms, but fall short on ability to target specific regions of the genome, generally only allowing random insertion of genetic material. In comparison, transposase technologies allow a greater degree of targeting, but leave unwanted traces of exogenous DNA in their wake. Other methods involve the introduction of naked DNA into the cell, which results in insertion into the genome at very low frequencies, usually at random, limiting this approach to organisms that can be economically cultivated at high densities and screened in large numbers. Simply put, most techniques for genetic manipulation are random, inefficient and leave a 'footprint' of foreign DNA. While this is usually tolerated in basic research, it is not acceptable for most commercial applications, and has been a major hurdle for GM animal technologies to date.
The advent of zinc finger nuclease (ZFN) technology represents a significant breakthrough for commercialisation of GM animal products, offering precisely targeted, efficient genome editing for the first time. Commercially available through Sigma Life Science under the CompoZr brand, this technique can be used to create permanent and heritable changes to an organism of interest.
This high degree of variability offers enormous potential for the textiles industry, raising the possibility of tailoring the properties of silk to create advanced technical fabrics
ZFNs are a class of engineered DNA binding proteins that facilitate targeted editing of the genome by creating double-strand breaks at user-specified locations. These breaks stimulate the cell's natural DNA repair mechanisms - homologous recombination (HR) and non-homologous end joining (NHEJ) - which can be exploited to achieve rapid and permanent site-specific modification of the desired genes. While HR can be used to insert foreign DNA sequences, NHEJ allows the cell's natural processes to create precisely targeted mimics of natural mutations which leave no traces of foreign DNA. Unlike previous techniques, ZFNs offer excellent sequence specificity, binding 24 to 36 base pair target sequences to virtually eliminate off target effects, and are able to achieve modification rates exceeding 20 %, well above rates for most other technologies.
The technique is already being used to create transgenic silkworms for spider silk production. By allowing precisely targeted insertion of spider genes and concomitant removal of endogenous silkworm silk genes at the same locus, ZFN technology offers the potential for development of transgenic silkworms which will produce native spider silk at commercially viable levels.
GM technologies have revolutionised the research world and have great potential in a variety of commercial applications, but have been limited by the inherent restrictions associated with historical GM technologies. The main drawback of these technologies is their inability to accurately and efficiently target genes of interest, instead relying on random insertion of genetic material into host genomes. These limitations result in the need for extensive and costly screening to identify animals with correct transgene expression (without compromising the viability of the animal), and also result in the co-expression of both the transgene and native homologues already present.
The advent of ZFN technology signifies the beginning of an exciting new chapter in the world of genetic modification, allowing precise, targeted and efficient genome editing for the first time. Production of native spider silk using transgenic silkworms is just one example of the potential commercial applications of this innovative technology, taking us one step closer to the reality of industrial scale biomanufacturing and paving the way for an entirely new spectrum of environmentally friendly materials.
Authors:
Joseph Bedell and Brian Buntaine
Commercial Animal Technologies Group, Sigma Advanced Genetic Engineering (SAGE) Labs, Sigma Life Science
HEADLINES FOR KRAIG BIOCRAFT LABORATORIES / (KBLB):
PHOTOS FROM VIETNAM POSTED JULY 6, 2018
ANN ARBOR, Mich., – January 7, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that it has successfully delivered the first two shipments of its highly specialized silkworms, which produce a silk with the physical characteristics of spider silk, to Vietnam.
Today’s announcement is the culmination of more than 5 years of work, and challenging negotiation, with the government of Vietnam. The silkworms from these first two shipments have already hatched and are now enjoying a fresh mulberry diet, so, for the first time in history, the global demand for spider silk materials has a viable, cost effective, and scalable solution.
“The dream of commercializing our powerful technology is now materializing. This marks a dramatic leap forward in Kraig Labs’ business plan for commercial production and mass marketing of cost effective recombinant spider silk, and becomes the foundation for an entirely new industry,” said, COO, Jon Rice. “To our long-term shareholders, who have taken this journey with us, as well as our team in the US and Vietnam, who have worked tirelessly to make this dream a reality, I cannot thank you enough. As we start the New Year, full of new opportunity, we truly have something incredible to celebrate.”
The Company has been working with leading sericulture experts, biotechnology institutions, and governmental agencies, in Vietnam, to further boost the silk industry with our revolutionary technology. Kraig Labs is currently finalizing renovation plans for a ~46,000 square foot production factory in Quang Nam Province, Vietnam.
“Our plan has always been to bring our technology to the silk producing regions of the world for rapid scale-up,” said, CEO and Founder, Kim Thompson. “Today we see the fruits of that effort. With its massive silk infrastructure and production capacity, Vietnam is an ideal location to launch our technology scale-up. Congratulations to our team and shareholders, as we prepare for the realization of large scale production.”
\
\
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |